UNIVERSITAS GADJAH MADA
Cost Effectiveness Analysis Letrozole dibanding Tamoksifen sebagai Terapi Adjuvan pada Pasien Kanker
Payudara ER/PR + HER 2 - Pascamenopause
LUCIA SHINTA RATNANINGTYAS, Prof. Dr. apt. Tri Murti Andayani, Sp. FRS
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Abraham, J., Aft, R., Agnese, D., Allison, K.H., Anderson, B., Blair, S.L., Burstein, H.J., Dang, C., Elias, A.D., Giordano, S.H., Kumar, N.R., Burns, J., Goetz, M.P., Goldstein, L.J., Hurvitz, S.A., Isakoff, S.J., Jankowitz, R.C., Javid, S.H., Krishnamurthy, J. & Young, J.S. (2021) *NCCN Clinical Practice Guidelines in Oncology: Breast Cancer*. National Comprehensive Cancer Network.

Boszkiewicz, K., Piwowar, A. & Petryszyn, P. (2022) 'Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients—A systematic review and meta-analysis', *Journal of Clinical Medicine*, 11(11). https://doi.org/10.3390/jcm11113133

Bradley, R., Burrett, J., Clarke, M., Davies, C., Duane, F., Evans, V., Gettins, L., Godwin, J., Gray, R., Liu, H., McGale, P., MacKinnon, E., McHugh, T., James, S., Morris, P., Pan, H., Peto, R., Read, S., Taylor, C. & Wood, W. (2015) 'Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials', *The Lancet*, 386(10001), pp. 1341–1352. https://doi.org/10.1016/S0140-6736(15)61074-1

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. & Jemal, A. (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide', *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424. https://doi.org/10.3322/caac.21492

Cai, Y., Dai, F., Ye, Y. & Qian, J. (2025) 'The global burden of breast cancer among women of reproductive age', *Scientific Reports*, 15(1), pp. 1–20. https://doi.org/10.1038/s41598-025-93883-9

Canreg FK-KMK UGM (2024) *Registrasi kanker berbasis rumah sakit RSUP Dr. Sardjito 2008–2021*. Yogyakarta: Universitas Gadjah Mada.

Coleman, R.E., Body, J.J., Gralow, J.R. & Lipton, A. (2008) 'Bone loss in patients with breast cancer receiving aromatase inhibitors', *Cancer Treatment Reviews*, 34(Suppl. 1).

Conte, P.F. & Frassoldati, A. (2007) 'Aromatase inhibitors in adjuvant treatment', *The Breast Journal*, 13(1), pp. 28–35.

Cuzick, J., Sestak, I., Bonanni, B., Costantino, J.P., Cummings, S., DeCensi, A., Dowsett, M., Forbes, J.F., Ford, L., LaCroix, A.Z., Mershon, J., Mitlak, B.H., Powles, T., Veronesi, U., Vogel, V. & Wickerham, D.L. (2013) 'Selective oestrogen receptor modulators', *The Lancet*, 381(9880), pp. 1827–1834.

Delea, T.E., Karnon, J. & Barghout, V. (2008) 'Cost utility analysis of letrozole versus tamoxifen', *European Journal of Health Economics*, 9(2), pp. 171–183.

Delea, T.E., El-Ouagari, K., Karnon, J. & Sofrygin, O. (2008) 'Cost-effectiveness of letrozole versus tamoxifen', *Breast Cancer Research and Treatment*, 108(3), pp. 375–387.

DeSantis, C.E., Ma, J., Gaudet, M.M., Newman, L.A., Miller, K.D., Sauer, A.G., Jemal, A. & Siegel, R.L. (2019) 'Breast cancer statistics, 2019', *CA: A Cancer Journal for Clinicians*, 69(6), pp. 438–451.

Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L. & Torrance, G.W. (2015) *Methods for the economic evaluation of health care programmes*. 4th edn. Oxford: Oxford University Press.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2015) 'Aromatase inhibitors versus tamoxifen', *The Lancet*, 386(10001), pp. 1341–1352.

Indonesia, Kementerian Kesehatan Republik Indonesia (2019) *Pedoman nasional pelayanan kedokteran kanker payudara*.

UNIVERSITAS
GADJAH MADA
Cost Effectiveness Analysis Letrozole dibanding Tamoksifen sebagai Terapi Adjuvan pada Pasien Kanker
Payudara ER/PR + HER 2 - Pascamenopause
LUCIA SHINTA RATNANINGTYAS, Prof. Dr. apt. Tri Murti Andayani, Sp. FRS
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Indonesia, Kementerian Kesehatan Republik Indonesia (2023) *Formularium nasional*.

Indonesia, Kementerian Kesehatan Republik Indonesia (2024) *Rencana kanker nasional 2024–2034*.

Li, Y. et al. (2022) 'Global burden of female breast cancer', *Frontiers in Oncology*, 12.

Lintermans, A. & Neven, P. (2015) 'Safety of aromatase inhibitor therapy', *Expert Opinion on Drug Safety*, 14(8), pp. 1201–1211.

Lux, M.P. et al. (2011) 'Cost-benefit analysis endocrine therapy', *Breast Care*, 6(5), pp. 381–389.

McDonald, E.S. et al. (2016) 'Clinical diagnosis and management of breast cancer', *Journal of Nuclear Medicine*, 57, pp. 9S–16S.

Miller, W.R. (2003) 'Aromatase inhibitors: Mechanism of action', *Seminars in Oncology*, 30(4 Suppl. 14), pp. 3–11.

Mouridsen, H. et al. (2009) 'Letrozole therapy alone or sequential', *New England Journal of Medicine*.

Neumann, P.J. et al. (2016) *Cost-effectiveness in health and medicine*. Oxford: Oxford University Press.

Sanders, G.D. et al. (2016) 'Recommendations for cost-effectiveness analyses', *JAMA*, 316(10), pp. 1093–1103.

Tan-Torres Edejer, T. et al. (2003) *Making choices in health: WHO guide to cost-effectiveness analysis*. Geneva: WHO.

Thürlimann, B. et al. (2006) 'Comparison of letrozole and tamoxifen', *New England Journal of Medicine*.

Uptodate (2025) *Strategy of adjuvant endocrine therapy*. Available at: https://www.uptodate.com

Windrasari, W., Wahyuni, F.S. & Khambri, D. (2019) 'Evaluasi terapi adjuvan hormonal', *Jurnal Sains Farmasi & Klinis*, 5(3), pp. 176.

Ye, M. et al. (2018) 'Economic evaluation of letrozole', *BioMed Research International*.

Zhang, J. et al. (2023) 'Global burden of female breast cancer', *Cancer Reports*, 6(S1).